Certain regulators of protein balance are suppressed in people with sporadic Parkinson’s disease and in those with familial disease linked to G2019S, the most common disease-causing LRRK2 gene variant, according to a study of patient-derived skin cells. These findings suggest shared underlying mechanisms between both types of Parkinson’s,…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $2.5 million research grant to advance the development of Soturi, Newel Health’s digital therapeutic app designed to help patients optimize their personalized treatment plan. The Soturi app is designed to deliver services to people with…
AC Immune has been awarded two research grants to identify the presence of TDP-43, a protein that plays a key role in neurodegeneration underlying Parkinson’s disease and other neurological diseases. The grants were awarded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Target…
Dosing has begun in a Phase 1 clinical trial of healthy volunteers to evaluate the safety and pharmacological properties of NEU-723, Neuron23’s oral investigational treatment for Parkinson’s disease. The small molecule candidate therapy is designed to block LRRK2, an enzyme coded by a gene of the same name whose…
Researchers have discovered a new genetic link between platelets in the bloodstream and Parkinson’s disease, according to a large-scale genetic study that investigated associations between blood measures and neurological and psychiatric diseases. Variation in platelet size, called platelet distribution width (PDW), was found to be broader in Parkinson’s patients…
Levels of nerve cell pentraxin proteins found in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord are associated with motor and cognitive decline in people with Parkinson’s disease and related conditions, a study suggests. As such, these nerve pentraxins may serve as predictive biomarkers for both…
The world-first Phase 3 clinical trial testing the ability of ambroxol, a medicine used for decades to treat lung conditions, to slow Parkinson’s disease progression is expected to start in the next few months. Called ASPro-PD, the end-stage trial is supported by results from the previous Phase 2…
A clinical trial testing the impact of low doses of psilocybin, a naturally occurring psychedelic compound, on inflammatory activity in people with Parkinson’s disease is on track to be completed by the end of February. Sponsored by Silo Pharma and conducted at the Clinical & Translational Science Institute (CTSI)…
Centogene is expanding enrollment in the Rockstock International Parkinson’s Disease (ROPAD) gene study — the world’s largest research effort to characterize the genetic profile of people with Parkinson’s disease. The global study now will recruit participants at 48 sites across 10 countries: the U.S., Argentina, Brazil, the…
Deferiprone, an iron chelator (binder) therapy, does not slow the progression of Parkinson’s disease in newly diagnosed patients who have never received treatment, according to data from a Phase 2 clinical trial. Instead, after about nine months of treatment in these patients, deferiprone was associated with a worsening of…
Get regular updates to your inbox.